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Abstract
The nuclear peroxisome proliferator-activated receptors (PPARs) α, β and γ activate the transcription of 
multiple genes involved in lipid metabolism. Several natural and synthetic ligands have been identified for 
each PPAR isotype but little is known about the phosphorylation state of these receptors. We show here 
that activators of protein kinase A (PKA) can enhance mouse PPAR activity in the absence and the 
presence of exogenous ligands in transient transfection experiments. The activation function 1 (AF-1) of 
PPARs was dispensable for transcriptional enhancement, whereas the activation function 2 (AF-2) was 
required for this effect. We also show that several domains of PPAR can be phosphorylated by PKA in 
vitro. Moreover, gel experiments suggest that PKA stabilizes binding of the liganded PPAR to DNA. PKA 
inhibitors decreased not only the kinase dependent induction of PPARs but also their ligand-dependent 
induction, suggesting that the ligands may also mobilize the PKA pathway to lead to maximal 
transcriptional induction by PPARs. Moreover, comparing PPARα KO with PPARα wild-type mice, we 
show that the expression of the ACO gene can be regulated by PKA-activated PPARα in liver. These data 
demonstrate that the PKA pathway is an important modulator of PPAR activity and we propose a model 
associating this pathway in the control of fatty acid β-oxidation under conditions of fasting, stress and 
exercise.
Keywords: Animals, Cell Line, Cholera Toxin, pharmacology, Cyclic AMP, analogs & derivatives, 
metabolism, Cyclic AMP-Dependent Protein Kinases, antagonists & inhibitors, physiology, Hepatocytes, 
drug effects, metabolism, Humans, Ligands, Male, Mice, Mice, Knockout, Models, Genetic, 
Oxidoreductases, genetics, metabolism, Phosphorylation, Promoter Regions (Genetics), Protein Isoforms, 
genetics, metabolism, Protein Structure, Tertiary, Pyrimidines, pharmacology, Receptors, Cytoplasmic and 
Nuclear, agonists, genetics, metabolism, Receptors, Retinoic Acid, physiology, Recombinant Fusion 
Proteins, metabolism, Retinoid X Receptors, Trans-Activation (Genetics), drug effects, Trans-Activators, 
genetics, metabolism, Transcription Factors, agonists, genetics, metabolism, physiology
INTRODUCTION
PPARα, β and γ (NR1C1, NR1C2, NR1C3)(1), which are encoded by separate genes and exhibit distinct 
tissue-distribution, belong to the nuclear receptor superfamily (2). This family includes receptors for sexual 
and adrenal steroids, retinoids, thyroid hormone, vitamin D, ecdysone, and a number of receptors whose 
ligands are still unknown and therefore are called orphan receptors (3, 4). PPARs were first shown to be 
activated by substances that induce peroxisome proliferation (5, 6). PPARs share a common structure of 5 
domains named A/B, C, D, E (the F domain is absent from PPARs compared with other members of the 
superfamily) (7). Key functions have been assigned to each of these domains (for review, (2, 8)). The 
N-terminal A/B domain contains the ligand-independent transcription activation function 1 (AF-1) (9). The 
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C domain has a characteristic helix-loop-helix structure stabilized by two zinc atoms and is responsible for 
the binding to peroxisome proliferator response elements (PPREs) in the promoter region of target genes. 
The D domain is a hinge region which can modulate the DNA binding ability of the receptor and which is 
involved in corepressors binding (10). The E domain has a ligand binding function and exhibits a strong 
ligand-dependent activation function (AF-2). In a classical manner, the ligand binding domain facilitates 
the heterodimerization of PPAR with the retinoid X receptor (RXR). In its active state, this heterodimer is 
able to associate with coactivators (11–13) and when bound to a PPRE to modulate the expression of target 
genes.
It was also recently demonstrated that phosphorylation can modulate PPAR activity (14–21), but there are 
no data available concerning the phosphorylation of PPAR by the protein kinase A (PKA) pathway. PKA 
activity is enhanced in the liver under conditions of stress, fasting or exercise (22, 23). Under these 
conditions, PPAR target genes such as AcylCoA Oxidase, are up-regulated (24–26).
The aim of this work was to investigate whether PKA activators, mimicking stress, fasting or exercise, 
could directly modulate the activity of PPARs. We performed a detailed analysis of the effects of PKA on 
the activity of the mouse PPARα, β and γ isotypes. We observed a PKA-dependent enhancement of the 
activity of all three isotypes in a ligand-independent and ligand-dependent manner on two distinct 
promoters. Several but not all PKA activators were able to produce this effect. Moreover, PKA inhibitors 
were able to repress the action of PKA activators. Very interestingly, PKA inhibitors were able to repress 
the effect of PPAR ligands by 50 to 75%, suggesting that these ligands are acting in part by recruiting the 
PKA pathway. By using GST fusions of PPARs, we demonstrate that PKA is able to phosphorylate 
different subdomains of PPARs in vitro, the DBD being the main phosphorylation target. Finally, using 
hepatocytes isolated from WT and PPARα KO mice, we show that PKA activators can enhance the 
expression of certain PPARα target genes and that PKA inhibitors repress WY 14, 643 dependent 
stimulation of these genes. These findings highlight the involvement of the PKA pathway in PPAR action 
and furthermore suggest that it is essential for the regulation of gene activation by PPAR ligands.
RESULTS
PKA activators enhance PPARα activity on PPRE containing promoters
To evaluate the effect of PKA on PPAR activity, we transfected HEK-293 cells with a mPPARα expression 
vector along with the PPRE-containing 2CYPA6-TK-CAT reporter construct or the TK-CAT construct as a 
control (Fig 1). Cells were treated or not with WY 14,643 (a PPARα ligand) and/or cholera toxin (CT) as a 
PKA activator. In the absence or the presence of cotransfected PPARα, expression of the TK-CAT 
construct was not significantly affected by WY 14, 643 nor by CT. In the absence of PPARα, the 2CYPA6-
TK-CAT construct, which contains functional PPREs (PPAR response element), was not stimulated by 
WY 14,643 nor by CT. When the PPARα expression vector was cotransfected, PPARα stimulated the 
activity of the 2CYPA6-TK-CAT construct in the presence of WY 14,643 (up to 7 fold compared to 
PPARα in the absence of ligand). Addition of CT to the WY 14,643 treatment produced a further 
enhancement of PPARα activity of about 2 fold compared to WY 14,643 treatment alone. In the absence of 
WY 14,643, CT by itself had also a stimulatory effect of about 2 fold. These results demonstrate that PKA 
activators can enhance PPARα activity.
Dose dependent activation of mouse PPARs by their ligands
To further evaluate the effect of PKA on mouse PPAR activity, we transfected mPPARα, β and γ 
expression vectors along with the 2CYPA6-TK-CAT reporter construct (Fig 2). Cells were treated or not 
with PPAR ligands (WY 14,643 for mPPARα, bromopalmitate for mPPARβ and BRL 49,653 for 
mPPARγ) and/or CT. PPARα stimulated the activity of the reporter construct in a WY 14,643 dose 
dependent manner. Addition of CT to the WY 14,643 treatment produced a further enhancement of PPARα 
activity even at saturating concentrations of WY 14,643. The same enhancement of activity by CT in the 
presence of ligand was obtained with PPARβ and with PPARγ. Since these observations were made with 
mouse PPARs, we tested whether amphibian PPARs would behave similarly. We observed that amphibian 
PPAR activity was also enhanced by PKA in a ligand-independent and ligand-dependent manner (data not 
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shown), thus suggesting that the PPAR response to the PKA pathway is well conserved throughout 
evolution.
PPAR activity enhancement by PKA can be obtained with PKA activators and mediated by 
different PPREs
To ensure that the results obtained above were not dependent on the 2CYPA6-TK-CAT reporter construct 
only, we tested the effect of PKA on the PPAR-dependent stimulation of the ACO-TK-CAT reporter 
construct (Fig. 3). This construct, which contains the PPRE containing region of the ACO gene promoter 
was inducible by mouse PPARα, β and γ in the presence of exogenous ligands, eventhough the effect was 
less pronounced than with the 2CYPA6-TK-CAT reporter gene. Addition of CT was able to increase PPAR 
activity 2 to 3 times. Interestingly, the ligand-independent effect of CT on PPAR activity was more 
pronounced on the ACO-TK-CAT reporter than on the 2CYPA6-TK-CAT reporter. These datasuggest that 
the enhancement by PKA of PPAR activity can be mediated by distinct PPREs.
To determine whether other PKA activators (see Fig. 4A) had similar effects as CT (a Gs protein activator), 
we tested 8-Br-cAMP (a cAMP analog), forskolin (an adenylate cyclase activator) and IBMX (a 
phosphodiesterase inhibitor) in transient transfection with the mouse PPARα expression vector and the 
2CYPA6-TK-CAT reporter construct (Fig. 4B). CT and forskolin had roughly the same activation ability, 
while 8 Br-cAMP and IBMX had no significant effect even when higher concentrations of these activators 
were used (data not shown). These results suggest that PKA activators acting directly on cAMP production 
are the major stimulators of PPAR activity.
Ligand activation of PPARs involves the PKA pathway
Next, we tested whether ligand activation of PPARs was also involving the PKA pathway, even in the 
absence of added PKA activators. To answer to this question, we used the H89 compound (a specific 
inhibitor of PKA at low concentrations) (27) in transient transfection experiments (Fig 5A). We observed 
that H89 was able to repress not only CT-dependent induction of PPARα, β and γ activity but also the 
ligand-dependent activation as well as the activation due to CT and ligand used together. In addition, the 
basal receptor activity, in the absence of exogenous ligand, was also repressed. These data suggest that 
PKA affects both the basal and ligand-regulated activities of the PPARs. To ensure that the effects 
observed with CT or H89 were not due a change in PPAR expression, we checked by western blot the 
levels of expression PPARα after treatment with WY 14,643, CT or H89 (Fig. 5B). PPARα protein was 
only detected after transfection of PPARα expression vector. Moreover, PPARα protein levels were 
unchanged following treatment with WY 14,643, CT or H89, alone or in combination. These data 
demonstrate that the effects observed in transfection assays are not due to changes in PPAR expression 
levels. We then checked whether these drugs could affect PPAR DNA binding. The same extracts as in 
Fig. 5B were used to perform a gel shift assay using the PPRE from the ACO gene (Fig. 5C). We observed 
a strong binding with PPARα WCE in the absence of added drug. Surprisingly, WY 14,643 treatment 
decreased PPARα DNA binding ability. CT also diminished PPARα DNA binding ability but to a lesser 
extent. More interestingly, the combination of WY 14,643 and CT enabled PPAR to bind to DNA more 
strongly than WY 14,643 or CT treatment alone. This in agreement with the situation observed for ERα for 
which PKA inhibits the dimerization of the receptor in the absence of ligand (28). Finally H89 had the 
same ability to reduce PPAR DNA binding as did WY 14,643. These data suggest that CT acts by 
stabilizing the decreased DNA binding ability of the liganded receptor in this in vitro assay.
RXR contributes to PPAR activation by PKA
As RXR is an obligate heterodimerization partner of the PPARs for DNA binding and transactivation, we 
determined whether RXR could be involved in the PKA activation of PPARα (Fig 6A). In the absence of 
transfected RXR or PPAR, the activity of the 2CYPA6-TK-CAT construct was very low and not modulated 
by the WY 14,643 and CT. In the absence of transfected RXR, transfected PPAR was active and modulated 
by PKA in HEK-293 cells, as these cells express low levels of endogenous RXR. In contrast, transfection 
of RXR alone in these cells had almost no effect on the expression of the 2CYP4A6-TK-CAT reporter gene 
even in the presence of 9-cis-retinoic acid (9cRA, is a ligand of RXR). However, we observed an 
enhancement of PPARα activity in the presence of 9cRA and CT both in the absence and in the presence of 
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WY 14,643. Indeed, enhancement of the PPARα activity was even more potent with CT + 9cRA than with 
WY 14,643 + 9cRA. On the contrary, in the presence of WY 14,643, 9c-RA had only a minor effect. By 
overexpressing simultaneously RXR and PPARα, in the absence of 9cRA, we observed an increase by 
about 30% of PPARα activation by WY 14,643, and a 2 fold activity enhancement in the presence of CT 
and without ligand compared to PPARα without cotransfected RXR. RXR affected only moderately 
PPARα activation (about 20%) by WY 14, 643 + CT. In the presence of RXR and 9cRA and in the absence 
of WY 14,643 and CT, we observed a 3 fold enhancement of PPARα activity compared to cells without 
9cRA. In the presence of WY 14,643 or WY 14,643 + CT, 9cRA only increased by 30% the activity seen 
in the absence of 9cRA. Finally, 9cRA was unable to affect CT induction of PPARα in the absence of WY 
14,643. These data suggest that RXR cooperates with PPARα in the absence of exogenous ligand to 
increase both the basal and CT-induced activity of PPARα on PPREs. We next checked whether RXR was 
itself the target of PKA when bound to its preferred binding site (DR1). To do so, we used the DR1-TK-
CAT construct containing a strong RXR binding site (Fig. 6B). We observed a strong activation of the 
construct by RXR in the presence of RA. CT treatment increased both ligand-independent and ligand-
dependent activity of RXR. Thus, RXR by being itself the target of PKA can enhance PPAR activity on 
PPREs.
AF-1 is dispensable for PPAR stimulation by PKA activators
In order to explore which domain of PPAR is the target of the PKA pathway, we created 3 truncated 
versions of PPARα (Fig 7A): one was deleted of the entire AB region (lacking AF-1, ΔAB mPPARα), and 
the 2 others lacked the AF-2 domain as the entire LBD (ΔLBD mPPARα) or the last 13 C-terminal residues 
(ΔAF2 mPPARα) were deleted (Fig. 7A). Surprisingly, the ΔAB mPPARα construct had roughly the same 
transactivation ability and exhibited the same enhancement of activity by CT as the wild-type mPPARα. 
On the contrary, the ΔLBD and ΔAF2 constructs were totally insensitive to WY 14,643 or CT treatments. 
These data suggest that the AF-2 region is the major mediator of the effects of PKA activators and that the 
AF-1 region is not essential. As a control, we checked the DNA binding ability of the mutants by 
performing a gel shift assay using ACO PPRE (Fig. 7B). We in vitro translated the different mutants and 
checked first that they were produced in similar amounts (data not shown). We observed that ΔAB had the 
same ability to bind to DNA as wild-type PPARα, whereas ΔAF2 and ΔLBD had a weak or not detectable 
binding ability respectively. This lack of binding of ΔLBD mutant is in agreement with previous reports 
(29). However, the weaker DNA binding ability of the ΔAF2 mutant cannot explain totally the lack of 
responsiveness to CT and we rather hypothesized that the AF2 function was involved in PKA stimulation. 
To confirm this hypothesis, we constructed GAL4 chimera comprising either the AB domain or the LBD of 
PPARα fused to the GAL4 DNA binding domain (Fig. 7C). In transfection assays in HEK-293 cells, the 
GAL-AF1 chimera exhibited a strong ligand independent activity. This product was insensitive to WY 
14,643 and CT alone or in combination, whereas the activity of the GAL-AF2 chimera was synergistically 
enhanced by WY 14,643 and CT treatments.
Interestingly, the GAL-AF2 chimera was not significantly affected by CT treatment alone, suggesting that 
other domains are involved in the effects of CT.
The main phosphorylation target of PKA activators is the DBD
To investigate which regions of PPARs were phosphorylated by PKA, we constructed a set of different 
GST fusion proteins corresponding either to the AB, DNA-binding (DBD) or ligand-binding (LBD) 
domains of the mouse PPARα and β. The fusion proteins produced in bacteria were then purified on GSH 
columns and submitted to PKA treatment with recombinant enzyme in the presence of γ-[ P]-ATP (
Fig. 8A). We observed a strong phosphorylation of the DBD and a weaker labelling of the LBD from 
PPARα and PPARβ, suggesting that the DBD is the main phosphorylation target. These data are in 
agreement with the effects of CT on DNA binding of PPARα (see above). Interestingly, the AB domain of 
mPPARα was also phosphorylated at a low level. We then mapped the putative sites of PKA 
phosphorylation (Fig. 8B). The most likely sites were mapped in the AB, C and E domain confirming that 
several domains of PPAR are potential targets of PKA phosphorylation.
PKA modulates PPARα target genes
32
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It was of interest to determine the effect of the PKA pathway on endogenous genes regulated by PPARα in 
vivo, and particularly in liver which is one of the main sites of PPARα action. To this end, isolated 
hepatocytes either from wild-type mice or from PPARα KO mice (30) were cultured in vitro and treated 
with PKA activators or inhibitors in the absence or the presence of WY 14,643. The expression of the ACO 
(peroxisomal acylCoA oxidase) and the FABP (fatty acid binding protein) genes, two PPARα target genes 
was analysed by northern blot (Fig. 9A). Under the conditions used, the ACO gene was not induced by WY 
14,643 alone in the cultured wild-type hepatocytes, possibly because of an unidentified limiting factor was 
lost, due to in vitro partial dedifferentiation of the hepatocytes (31). However, CT was able to weakly 
stimulate ACO gene expression in the absence of WY 14,643, but CT was a strong activator in the presence 
of WY 14,643. These data underline the ability of PKA activators to potentiate PPARα ligand-dependent 
activation. In contrast, PPARα KO hepatocytes were not sensitive to CT nor to WY 14,643 treatment, 
demonstrating that PPARα was required for the WY 14,643 and CT synergism in the stimulation of the 
ACO gene. The expression of the FABP gene was strongly enhanced by WY 14,643 in wild-type 
hepatocytes but not in PPARα KO hepatocytes, suggesting that distinct factors are required for ACO and 
FABP stimulation by PPARα. In wild-type hepatocytes, addition of CT did not significantly affect FABP 
expression in the absence and in the presence of WY 14,643. On the contrary, H89 reduced by about 90% 
the WY 14,643 induction of FABP expression, which is in agreement with our transfection experiments. In 
PPARα KO hepatocytes, the expression of the FABP gene was not significantly affected by WY 14,643, 
CT or H89, demonstrating that PPARα was required for FABP induction. In conclusion, our data suggest 
that ligand and PKA activation of PPARα converge in the stimulation of the PPAR target genes in 
hepatocytes.
DISCUSSION
Among the different stimuli known to phosphorylate and modulate nuclear receptor activity, the PKA 
pathway is certainly one of the best studied. However, no data are yet available concerning the potential 
effect of PKA on PPAR activity. This is in contrast with several studies focusing on PPAR phosphorylation 
by other stimuli. The scope of this work was to evaluate the role of PKA in modulating PPAR activity.
Early work from Shalev et al. (14) has shown that insulin treatment can phosphorylate PPARα. Insulin can 
also increase PPARα, and PPARγ2 activity in transient transfections. Insulin stimulation of PPARγ 
involves MAP kinases (15, 19). On the contrary, other pathways stimulated by EGF (epidermal growth 
factor) and PDGF (platelet-derived growth factor) also involving MAP kinase have a negative effect on 
mPPARγ1 activity by phosphorylating serine 82 in the AB domain, which corresponds to serine 112 of 
mPPARγ2 (16, 17, 20). Further studies have demonstrated that this negative effect of MAP kinase was due 
to the inhibition of ligand binding consequent to an alteration of the three-dimensional structure of the 
receptor (32).
Here we demonstrate by transient transfection experiments that PKA activators can stimulate PPAR 
activity in an exogenous ligand-independent manner. Moreover, a combination of PKA activators and 
PPAR ligands leads to an increased activation of PPAR target genes. Interestingly, this effect was obtained 
even at saturating concentrations of PPAR ligands. Moreover, we show that these effects are not due to 
change in PPAR expression. This stimulatory effect of PKA is in agreement with the results obtained with 
other nuclear receptors. Most studies report an activation of nuclear receptors such as estrogen receptor 
(ERα), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor (PR), 
androgen receptor (AR) or steroidogenic factor-1 (SF-1) by PKA (28, 33–38), whereas HNF4 has been 
shown to be down-regulated by PKA (39). Moreover, PKA activated PPARs were able to stimulate two 
types of PPREs, even though the amplitude of response was different. Interestingly, PKA activators were 
nearly as effective as PPAR ligands to activate the ACO PPRE, whereas they could only activate the 
CYPA6 PPRE to levels corresponding to 25–30% of those obtained with PPAR ligands. Such differences 
were also found with ERα according to the cell-type and the promoter used (40–42).
Using different PKA pathway activators, we observed that the most potent ones were those affecting 
adenylate cyclase activity and not those leading to a direct increase of cAMP such as supplementation with 
cAMP analogs or inhibition of phosphodiesterase activity. To address the question whether ligands by 
themselves would activate the PKA pathway, we treated cells with H89, an inhibitor of PKA (27). 
Interestingly, we observed that H89 could reduce not only the CT induction of PPARs but also their 
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induction by ligands such as WY 14,643, bromopalmitate and BRL 49,653, suggesting that these ligands 
act in part through the PKA pathway. This result was not due to a change in PPAR levels as shown by 
western blot. An attractive hypothesis would be that the ligands can also act indirectly by modulating 
intracellular cAMP levels. Such observations have indeed been reported for estrogens, which are able to 
increase intracellular cAMP levels, which in turn activate PKA and increases ERα activity (34).
As PPARs act essentially as heterodimers, it was of particular interest to determine whether its heterodimer 
partner (RXR) could be involved in PPAR activation by PKA. Surprisingly, in the absence of 9-cis-retinoic 
acid (RXR ligand), cotransfection of RXR moderately affected PPARα activity in the presence of WY 
14,643, but increased PPARα activity by about 2 fold without any ligand, leading to an activation by CT 
equal to the one with WY 14,643. In the presence of RA, RXR conferred an even stronger ligand-
independent activity to PPARα. This could be explained by the fact that RXR is itself the target of PKA as 
shown clearly on DR1-TK-CAT construct. RAR and RXR activation by PKA have been previously 
reported (43–45).
Thus, in the absence of WY 14,643 but in the presence of RA, it seems that the PKA action on RXR 
heterodimerized with PPAR leads to a major enhancement of the activity of PPAR/RXR heterodimers. 
However, we cannot exclude the possibility that other factors such as coactivators could also be the target 
of PKA.
Using truncated PPARα constructs, we determined that the AF-2 domain was most important for 
transactivation by PKA. Deletion of the AB domain from PPARα only slightly affected its basal and ligand 
induced activity, which is in agreement with previous data (29).Interestingly, CT was still able to potentiate 
WY 14,643 induction of the truncated PPARα, demonstrating that the AF-1 function was not involved in 
the potentiation by PKA. On the contrary, AF-2 deletion completely abolished WY 14,643 as well as CT 
activation of PPARα. Our data obtained with the GAL4 chimeras clearly confirm that AF2 but not AF1 is 
the target of PKA action. The demonstration that AF2 is the target of PKA is in agreement with the results 
found for PKA activation of ERα (42, 46) or SF-1 (38). However, for AR (37) and MR (47), the N-terminal 
portion seemed to be involved in PKA effects. Interestingly, CT had no effect on the ligand-independent 
activity of the GAL-AF2 chimera suggesting that other domains of the receptors are necessary. To better 
characterize the domains involved, we analysed the phosphorylation of different domains of PPAR by 
using GST-PPAR fusions. We observed a very strong phosphorylation of the DBD, a weaker one for the 
AB domain and a faint one for the LBD, again suggesting that several domains are involved in the 
activation of PPARs by the PKA pathway. This result is confirmed by the mapping of the most conserved 
putative PKA sites which are present in the A/B, DBD and LBD domains. As the main phosphorylation site 
is present in the DBD, we analysed whether the drugs used could modulate the DNA binding ability of 
PPARα in vitro. To our surprise, WY 14,643 and CT strongly inhibited PPARα DNA binding. However, 
cotreatment with WY 14,643 and CT led only to a limited decreased binding. We thus propose that CT acts 
in part by preventing the decreased binding of PPAR liganded with WY 14,643. This stabilization would in 
turn increase PPAR activity. This in agreement with a previous report (28), which shows that ERα DNA 
binding is inhibited by PKA only in the absence of estradiol. This report also shows that the target of PKA 
is in the DBD of ERα. Rangarajan et al. (33) have also demonstrated that PKA enhancement of liganded 
GR required specific residues of the DBD. In this case, however, they observed an enhancement of GR 
binding in the presence of PKA. This suggested that depending on the receptors, the mechanisms of 
enhancement of the activity by PKA requires different functions of the receptor.
A crucial question was whether PKA does modulate the expression of PPAR target genes? To answer this 
question, we focused on the role of PPARα in the liver and took advantage of PPARα KO mice. We 
analysed the expression of two target genes, ACO and FABP (48, 49). In wild-type mice hepatocytes 
cultured in vitro, we demonstrated that cotreatment with WY 14,643 and CT led to a synergistic activation 
of the ACO gene expression. On the other hand, the FABP gene was only weakly affected by addition of 
exogenous PKA activators, but addition of PKA inhibitors strongly diminished its induction by WY 
14,643, confirming the results obtained in transient transfection experiments. In PPARα KO mice, ACO 
was not subjected to stimulation by WY 14,643 or CT alone or in combination, confirming that PPARα 
was essential to PKA activation of the ACO gene. In these mice, FABP induction by WY 14,643 was 
completely abolished. FABP which is involved in fatty acid (FA) binding in hepatocytes and ACO in 
β-oxidation of FA could therefore be integrated in the following model involving the PKA pathway (
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Fig 9B): Under conditions of stress, fasting or exercise, the limiting factor for brain and muscles rely on 
increased energy fuel availability, essentially glucose and ketone bodies. One way for the organism to meet 
these needs is to stimulate gluconeogenesis and ketogenesis. The adipose tissue hydrolyses triglycerides 
(TG) to liberate free non esterified fatty acids, which are released into the blood circulation and are then 
rapidly taken up by the liver to be transformed into ketone bodies. PPARα and PPARγ are directly involved 
in the regulation of several key enzymes of these pathways. Stress, fasting or exercise are also associated 
with an increased glucagon production (one of the key factors increasing cAMP levels in cells and thus 
activating PKA) by the adrenal gland (50). PKA increases PPARα activity in liver, which in turn stimulates 
the β-oxidation and in particular the conversion of FA into acetyl-CoA used in the production of ketone 
bodies (51). Results from our laboratory (52) have also demonstrated that fasting did not affect FABP 
expression in wild-type mice. On the contrary, ACO gene expression has been shown to be up-regulated by 
fasting in wild-type mice but not in PPARα KO mice (24, 26), confirming the scheme of regulation we 
propose. In addition, PPARα KO mice exhibited an increased accumulation of FA in liver, due to impaired 
β-oxidation (53).
In conclusion, our results suggest that under conditions of stress, fasting and exercise, PPARα activity is 
increased by the PKA pathway and leads to an enhancement of β-oxidation, production of glucose and 
ketone bodies, which serve as fuel for muscles and brain.
MATERIALS AND METHODS
Chemicals
Bromopalmitate, CT (cholera toxin), Forskolin, 8-Br-cAMP (8-Bromoadenosine 3′:5′-cyclic 
monophosphate), IBMX (isobutyl methylxanthine) were from Sigma (St Louis, MO). WY 14,643 was from 
Chemsyn Science Laboratories (Kansas, USA). BRL 49,653 was a kind gift from Parke Davis. H89 
(N-[2-((p-Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 2HCl) was from Calbiochem (La 
Jolla, CA). PKA catalytic subunit was from Promega (Madison, WI).
Oligonucleotide Sequences
ACO1: GCCACCGCCTATGCCTTCCACTTT
ACO2: CGGCTTGCACGGCTCTGTCTTGA
LPL1: CCTGCGGGCCCTATGTTTG
LPL2: CTCGCCGATGTCTTTGTCCAGT
mFABP1: CAATTGCAGAGCCAGGAGAACTTT
mFABP2: CAATGTCGCCCAATGTCA
Plasmids
The reporter plasmid 2CYP-TK-CAT contains two copies of the CYP4A6 PPRE cloned in opposite 
orientation upstream of the minimal herpes simplex virus thymidine kinase promoter in the pBLCAT8+ 
plasmid (54). ACO-TK-CAT plasmid corresponds to the Acyl-CoA oxidase promoter PPRE cloned in 
PBLCAT8+ as described by Dreyer et al. (6). DR1-TK-CAT corresponds to the perfect DR1 sequence 
(AGCTTCATTCTAGGTCAAAGGTCATCCCCT) cloned in the pBLCAT8+ plasmid. pG5CAT reporter 
plasmid (Clontech) corresponds to 5 Gal4 binding sites upstream of the E1b minimal promoter. Mouse and 
Xenopus PPAR α, β and γ cDNAs were cloned into the BamHI site of the pSG5 mammalian expression 
vector. For PKA in vitro assays, portions of mouse PPAR cDNAs were amplified by PCR and then 
subcloned into the BamHI site of the prokaryotic expression vector pGEX1. mPPARα AB (aa 1–101) was 
cloned into the SmaI/BamHI sites of pGEX1. mPPARα DBD domain (aa 98–203), mPPARβ DBD domain 
(aa 68–129), mPPARα LBD (aa 202–468) and mPPARβ LBD (aa 136–396) were cloned into the BamHI 
site of pGEX1. pSG5-mPPARα ΔAB was obtained by removing aa 1 to 101 from WT mPPARα by PCR 
and pSG5-mPPARα ΔLBD by removing sequences downstream from residue 247. pSG5-mPPARα ΔAF2 
was obtained by removing the last 13 residues from WT mPPARα. GAL-AF1 and GAL-AF2 expression 
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plasmids correspond to AB domain (aa 1 to 100) LBD domain (165–468) respectively cloned in Gal4 DBD 
pM vector (Clontech).
In vitro Translation
In vitro translation was performed using the TNT Promega kit. Briefly, 1 μg of expression vector was 
mixed to 25 μl of TNT rabbit reticulocyte lysate, 2 μl of TNT buffer, 1 μl of mix containing all amino 
acids, 1 μl of RNAsin (50 U/μl), 1 μl of T7 RNA polymerase (20 U/μl). A control reaction was performed 
under the same conditions but [ S]-methionine (15 μCi/μl) was used to label the protein produced. The 
final reaction volume was 50 μl. The reaction was performed for 1.5 h at 30 °C. The translation efficiency 
was checked by loading 1 μl of labelled lysate on an SDS-PAGE gel.
Gel Mobility Shift Assays
Gel mobility shift assays were carried out as previously described (55). Briefly, [ P]-labeled ACoA 
(GATCCCGAACGTGACCTTTGTCCTGGTCCCGATC) double strand oligonucleotide, (56) was 
combined with in vitro translated PPAR or HEK-293 WCE and when indicated mouse RXRβ  Sf9 cellular 
extract. Protein-DNA complexes were separated from the free probe by non-denaturating gel 
electrophoresis with 4% polyacrylamide (29/1) gels in 0.5 X TBE.
Cell Culture and Transient Transfection
HEK-293 cells (human embryonic kidney cells) were cultured in 10% FCS (foetal calf serum) DMEM-F12 
with 5% CO . Cells were plated in 24-well plates in 10% CDFCS, phenol-free DMEM 24 h before 
transfection. Transfections were performed by lipofection (lipofectamine, Life Technologies, Rockville, 
MA) using 200 ng of CAT reporter construct, 400 ng of the internal reference β-galactosidase reporter 
plasmid (pCH110) and 100 ng of pSG5-PPAR or pSG5-hRXRα expression vectors per well. After 
lipofection, the cells were grown in 10% CDFCS, DMEM in the presence of different ligands for 36 h. 
Transactivation ability was determined by CAT activity on the whole cell extract as previously described 
(55).
Hepatocyte Isolation and Culture
Hepatocytes were isolated from liver of adult male wild-type (SV129) or PPARα KO mice using a two-step 
in situ portal vein collagenase A (Boehringer Mannheim) perfusion method (57). Freshly isolated 
hepatocytes were filtered through nylon membrane to remove tissue debris and cell clumps. The cell 
suspension was washed in Leibovitz’s L-15 medium and resuspended twice after centrifugation. The 
isolated hepatocytes were suspended in William’s medium E supplemented with 10% FCS, 100 μg/ml 
streptomycin and 100 μg/ml penicillin and seeded in dishes at the density of 5.10  cells/ml medium. The 
medium was renewed 4 hr later to remove dead cells. Cells were then treated with or without WY 14,643 
(10 μM) and cholera toxin (1 μg/ml), in presence or not of H89 (10 μM). Cultures were maintained at 37°C 
in a humidified air/CO  incubator (5% CO , 95% air) for 24 h.
Whole cell extract preparation and western blot
HEK-293 cells were harvested, washed in PBS, and resuspended in TEG (10 mM Tris-HCl, pH 7.4, 1.5 
mM EDTA, and 10% glycerol)/0.4 M KCl containing 5 μg/ml aprotinin, leupeptin and pepstatin A and 0.1 
mM phenylmethylsulfonyl fluoride. Then, cells were sonicated and the cellular debris were pelleted by 
centrifugation at 14000 rpm for 20 minutes in microfuge tubes. Thirty μg of whole cell extract proteins 
were subjected to SDS-PAGE followed by electrotransfer onto a nitrocellulose membrane. The blot was 
probed with anti PPARα AB antibody (1/1000) (polyclonal rabbit antibody produced in our laboratory and 
directed against mouse PPARα AB region) and then incubated with rabbit anti-rabbit IgG horseradish 
peroxydase conjugated antibody (1 μg/ml). ECL kit from Amersham (Arlington, IL, USA) was used for 
protein detection.
RNA Isolation and Northern Blot
Total RNA was isolated from isolated hepatocytes using the Trizol reagent from Life Technologies 
(Rockville, MA) as described by the manufacturer. ACO and FABP probes were amplified by RT-PCR. 
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The amplifying primers were: ACO1 and ACO2 primers for mouse peroxisomal acylCoA oxidase (ACO) 
probe (1036–1690), mFABP1 and mFABP2 for mouse fatty acid binding protein (FABP) probe (61–394) 
(see above). For northern blot analysis, 20 μg of total RNA was electrophorized in a 2.2 M 
formaldehyde-1% agarose gel in MOPS buffer and then hybridized with the different probes as previously 
described (58).
Production of GST Fusion Proteins
Production of GST fusion proteins was performed as previously described (13). Protein concentration was 
estimated by the Bradford method. The levels of expressed fusion proteins were determined by an in vitro
binding assay followed by a SDS-PAGE gel and a Coomassie Blue staining.
In vitro PKA Assays with Glutathione Sepharose
Glutathione Sepharose (Pharmacia Biotech, Uppsala, Sweden) was equilibrated with NET binding buffer 
(150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA). Crude bacterial extract containing GST fusion 
proteins was incubated at 4 °C with 25 μl of beads for 2.5h. After 2 washes with NETN (NET + 0.5% 
NP40), the beads were washed 2 times with PKA buffer (50 mM Tris-HCl (pH 7.5), 10 mM NaCl, 1 mM 
DTT, 10 mM MgCl , 10% glycerol). The beads were then incubated in a mix containing 50 μl of PKA 
buffer, 45U of PKA catalytic subunit, 0.5 μl γ-[ P]-ATP and 0.5 μl ATP 2.5 mM for 45 min at 30 °C. 
After 2 washes with NETN, beads were boiled in SDS loading buffer, and a quarter of the proteins were 
run on SDS-PAGE. The gel was then stained with coomassie blue. After extensive washes with a solution 
containing 20% methanol and 10% acetic acid, the gel was submitted to autoradiography.
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AF activation domain 
Bro bromopalmitate 
8-Br-cAMP 8-Bromoadenosine 3′:5′-cyclic monophosphate 
CAT chloramphenicol acetyl-transferase 
CT cholera toxin 
DBD DNA binding domain 
FSK forskolin 
GST glutathione S-transferase 
H89 N-[2-((p-Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 2HCl 
IBMX isobutyl methylxanthine 
LBD ligand binding domain 
PAGE polyacrylamide gel electrophoresis 
PKA protein kinase A 
PPAR peroxisome proliferator-activated receptors 
RXR retinoid X receptor 
TK thymidine kinase 
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Fig 1
CT increases mPPARα activity on a PPRE containing promoter
Mouse PPARα was transfected along with TK-CAT or 2CYPA6-TK-CAT constructs in HEK-293 cells. Transfections were 
with 200 ng of TK-CAT or 2CYPA6-TK-CAT reporter construct and without or with 100 ng of pSG5-mPPARα expression 
vector per well. Cells were grown for 36 h in the presence of 1 μM of WY 14,643 (WY), with or without 1μg/ml CT. 
Results are shown as the mean ± SD (n = 6) of CAT activity after normalization for β-galactosidase activity.
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Fig 2
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CT increases mPPAR activity at various concentrations of PPAR ligands
Mouse PPARα, β and γ were tested for their ability to respond to CT in HEK-293 cells. Transfections were with 200 ng of 
2CYPA6-TK-CAT reporter construct and 100 ng of pSG5-mPPARα, β and γ expression vectors per well. Cells were grown 
for 36 h in the presence of various concentrations of WY 14,643 (WY), Bromopalmitate (Bro) and BRL 49,653 (BRL), 
with or without 1μg/ml CT. Results are shown as the mean ± SD (n = 6) of CAT activity after normalization for 
β-galactosidase activity.
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Fig 3
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PKA enhancement of PPAR activity via the ACO PPRE
Mouse PPARα, β and γ cDNAs were cotransfected in HEK-293 cells with ACO-TK-CAT reporter construct instead of the 
2CYPA6-TK-CAT reporter construct in the same conditions as in fig 1. Cells were grown for 36 h in the presence of 1 μM 
WY 14,643 (WY), 50 μM Bromopalmitate (Bro) and 5 μM BRL 49,653 (BRL), with 1μg/ml CT when indicated. Results 
are shown as the mean ± SD (n = 6) of CAT activity after normalization for β-galactosidase activity.
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Fig 4
various PKA activators stimulate PPAR activity
A. Schematic representation of the PKA pathway. cAMP is produced from ATP by a membrane-bound adenylate cyclase 
(Ac). Transmembrane receptors (R) for numerous hormones, neurotransmitters and other stimuli (H) are coupled to 
adenylate cyclase via heterotrimeric G-proteins (α, β and γ subunits). This interaction promotes the exchange of GDP, 
bound to the α-subunit, for GTP and the subsequent dissociation of the α subunit form the βγ heterodimer. The Gα-GTP 
then binds to adenylate cyclase and modulates its activity. PDE: phosphodiesterase; FSK: forskolin; CT: cholera toxin;. B.
100 ng of pSG5-mPPARα was cotransfected in HEK-293 cells with 2CYPA6-TK-CAT reporter construct under the same 
conditions as in Fig 1. Cells were grown for 36 h in the presence of 1 μM of WY 14,643 (WY), with 1μg/ml Cholera toxin 
(CT), 50 mM 8-BrcAMP, 200 μM forskolin (FSK) or 10 μM IBMX when indicated. Results are shown as the mean ± SD 
(n = 3) of CAT activity after normalization for β-galactosidase activity.
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Fig 5
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PKA inhibitors can repress PPAR activity
A. Mouse PPARα, β and γ were tested for their ability to respond to CT in HEK-293 cells using 200 ng of 2CYPA6-TK-
CAT reporter construct and 100 ng of pSG5-PPAR expression vectors. After lipofection, 10 μM of H89 was added to the 
medium 1 h before ligands. Cells were grown for 36 h in the presence of 1 μM WY 14,643 (WY), 50 μM Bromopalmitate 
(Bro) and 5 μM BRL 49,653 (BRL), with 1μg/ml CT when indicated. Results are shown as the mean ± SD (n = 6) of CAT 
activity after normalization for β-galactosidase activity. B. 30 μg of whole cell extracts from transfected cells were loaded 
on SDS-PAGE and probed by western blot using mPPARα antibody. The first lane corresponds to HEK-293 cells 
transfected with the empty pSG5 vector and the remaining lanes correspond to 293 cells transfected with pSG5-mPPARα 
vector and treated or not (−) with WY, CT or H89 under the same conditions as in Fig. 5A. C. 5 μg of the same WCE were 
used in gel shift assays using the ACoA probe.
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Fig 6
RXR modulates PPAR activity in the presence of PKA activators
A. 100 ng of pSG5, pSG5-mPPARα and pSG5-mRXRβ2 expression vectors per well in combination or alone were 
cotransfected in HEK-293 cells with 200 ng of 2CYPA6-TK-CAT reporter construct. After lipofection, cells were grown 
for 36 h with or without 1 μM of WY 14,643 (WY), and 1 μM 9-cis retinoic acid (RA), with 1μg/ml CT when indicated. 
Results are shown as the mean ± SD (n = 6) of CAT activity after normalization for β-galactosidase activity. B. 100 ng of 
pSG5 or pSG5-mRXRβ2 expression vectors were cotransfected in HEK-293 cells with 200 ng of DR1-TK-CAT reporter 
construct per well. After lipofection, cells were grown for 36 h with or without 1 μM 9-cis retinoic acid (RA) and 1μg/ml 
CT when indicated. Results are shown as the mean ± SD (n = 6) of CAT activity after normalization for β-galactosidase 
activity.
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Fig 7
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The AB domain is dispensable for PPAR response to PKA
A. 100 ng of pSG5-mPPARα WT, or pSG5-mPPARα ΔAB, pSG5-mPPARα ΔLBD, or pSG5-mPPARα ΔAF2 constructs 
were transfected in HEK-293 cells with 200 ng of 2CYPA6-TK-CAT reporter construct per well. After lipofection, cells 
were grown for 36 h with or without 1 μM of WY 14,643 (WY) with or without 1μg/ml CT. Results are shown as the mean 
± SD (n = 6) of CAT activity after normalization for β-galactosidase activity. B. Equivalent amounts of in vitro translated 
mPPARα WT, mPPARα ΔAB, mPPARα ΔLBD, or mPPARα ΔAF2 receptors were used in gel shift assays in combination 
with the ACoA probe. Lane 1 corresponds the probe alone and lane C to mock lysate. In addition, mouse RXRβ  Sf9 
cellular extract was eventually added (RXR). The arrow indicated the position of RXR retarded complex and the star the 
position of a non specific complexes. C. 100 ng of GAL, GAL-AF1, or GAL-AF2 constructs were transfected in HEK-293 
cells with 200 ng of pG5CAT reporter construct. After lipofection, cells were grown for 36 h with or without 1 μM of WY 
14,643 (WY) with or without 1μg/ml CT. Results are shown as the mean ± SD (n = 6) of CAT activity after normalization 
for β-galactosidase activity.
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Fig 8
PPAR phosphorylation in response to PKA occurs mainly in the DBD
A. Regions encoding AB (ABα), DBD (DBDα) and LBD (LBDα) domains of mPPARα as well as DBD (DBDβ) and LBD 
(LBDβ) of mPPARβ were cloned in pGEX1 prokaryotic expression vector as GST fusions. In vitro PKA assay was 
performed as described in the Materials and Methods. The upper panel corresponds to the gel autoradiogramm and the 
lower panel to the protein expression levels after coomassie blue staining of the gel. The arrow labelled NS corresponds to 
a non specific band. B. Mapping of the main putative PKA sites of phosphorylation on mPPARα.
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Fig 9
PKA modulates some PPAR target genes
A. Hepatocytes were isolated from wild-type and PPARα KO mice and cultured in Williams medium supplemented with 
10% CDFCS. Cells were then treated for 24 h with or without 10 μM WY 14,643 (WY) and 1 μg/ml cholera toxin (CT). 
When H89 was used (H: 10 μM), it was added to the medium 1 h before treatment with WY or CT. After RNA extraction, 
10 μg of total RNA were used for northern blotting and then hybridized sequentially with ACO, FABP and 28S probes. The 
figure shows a representative experiment. B. General model of cross-talk between fatty acids and PKA signalling involving 
PPARs. TG: triglycerides, FA: fatty acids, Glucocor: glucocorticoids, β OX: β oxidation, LPL: lipoprotein lipase.
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